Diclofenac targeting brain chemistry in alcohol use disorder
Proof of concept: diclofenac as a KMO inhibitor in AUD
This project looks at whether the common pain reliever diclofenac can shift brain chemicals linked to alcohol use disorder to reduce drinking-related problems.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11195617 on NIH RePORTER |
What this research studies
You would be hearing about work that tests diclofenac, an FDA-approved anti-inflammatory, to block the enzyme KMO that shifts the kynurenine pathway toward harmful brain chemicals linked to alcohol problems. The team will use laboratory models and biochemical measurements to see whether diclofenac raises protective kynurenic acid and lowers toxic quinolinic acid in the brain and whether those changes reduce alcohol-seeking behaviors. These are proof-of-concept experiments meant to support future clinical trials in people with alcohol use disorder. The research is led by investigators at the University of Maryland Baltimore.
Who could benefit from this research
Good fit: Adults with alcohol use disorder, particularly those with heavy drinking or a history of relapse, would be the most relevant candidates for eventual clinical testing.
Not a fit: People without alcohol use disorder or those who cannot take NSAIDs because of stomach ulcers, kidney disease, bleeding risk, or allergy are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could repurpose an existing drug to help lower craving and relapse in people with alcohol use disorder.
How similar studies have performed: Animal studies have shown KMO inhibition can reduce alcohol self-administration and relapse-like behaviors, but KMO-targeting drugs have not yet been tested in people and repurposing diclofenac is a novel approach.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Roche, Daniel — University of Maryland Baltimore
- Study coordinator: Roche, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.